Assessing Efficacy of Fibroblast Cell Therapy in MS: Hamid Khoja, PhD
The chief scientific officer of FibroBiologics discussed efficacy findings from a phase 1/2 trial.
Assessing Safety of Fibroblast Cell Therapy in Multiple Sclerosis: Hamid Khoja, PhD
The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology in MS.
Fibroblast Cell Therapy or Stem Cell Therapy for MS: Hamid Khoja, PhD
The chief scientific officer of FibroBiologics discussed the advantages of fibroblast cell therapy over stem cell therapy.